JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.
JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.